Ticker

Executive Accountability: Chief Revenue Officer Chen Fang Signed BitGo's Registration Statement That Allegedly Concealed the True Severity of Digital Asset Price Risks, Contributing to Investor Losses Executive Accountability: Chief Revenue Officer Chen Fang Signed BitGo's Registration Statement That Allegedly Concealed the True Severity of Digital Asset Price Risks, Contributing to Investor Losses

MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer.